Key result
Serum betatrophin levels were significantly elevated in patients with Type 1 diabetes (322.73 ng/l) compared to those with Type 2 diabetes (144.84 ng/l) and healthy controls (106.19 ng/l).
Why the study?
Previous studies of betatrophin were mainly conducted under insulin-resistant conditions, with limited data in T1DM and no consensus regarding its association with diabetes.
Cross-Sectional (n=162)
No
Absolute Event Rate: 322.73% vs 106.19%
p-value: p=0.0001
Circulating betatrophin levels are significantly elevated in T1DM but correlate with markers of glycemic control in T2DM, suggesting different metabolic roles in these diabetes subtypes.
Betatrophin elevation in T1DM should not yet alter management; leaves open subtype-specific biomarker or therapeutic roles for prospective validation.
Background: Betatrophin is a newly identified liver-derived hormone that is associated with glucose homeostasis and lipid metabolism. Previous researches of betatrophin on glucose and lipid metabolism were mainly done under insulin resistant conditions. Only three studies from two centers investigated the association between betatrophin and type1 diabetes mellitus (T1DM). There is no consensus about the association of diabetes and betatrophin levels. Main purpose of this study was to investigate the relationship between betatrophin and various markers affecting glucose and lipid metabolisms in T1DM, type 2 diabetes mellitus (T2DM) and control subjects. Methods: T1DM (n: 64), T2DM (n: 67) and control subject (n: 31) enrolled in this study. All subjects' physical examination, measurements of antropometric parameters and blood pressures were documented. Insulin, C-peptide, HbAIc, triglyceride, LDL-C, HDL-C, CRP, microalbuminuria, and betatrophin levels were measured in all groups. Results: Serum betatrophin levels were significantly increased in patients with T1DM (p: 0.0001). Betatrophin was correlated with LDL-C in T1DM (r: 0.265, p: 0.034). No relationship between betatrophin and glucose metabolism (FBG, HbA1c) in T1DM was observed. Serum betatrophin levels were not increased in T2DM patients. Further more, we observed a significant positive correlation between betatrophin and FBG (r: 0.289, p: 0.019) and HbA1c (r: 0.372, p: 0.002) in T2DM. As distinct from previous studies we did not find any relationships between betatrophin and insulin resistance in any groups. Conclusions: Betatrophin is significantly higher in T1DM. Betatrophin levels correlated positively with markers of glycemic control in T2DM. Circulating betatrophin levels appeared to be the metabolic parameters of the T2DM rather than T1DM.
No takes yet. Share an insight, caveat, or question.
Esma et al. (2021) conducted a cross-sectional in Type 1 and Type 2 Diabetes Mellitus (n=162). Type 1 Diabetes Mellitus vs. Healthy controls and Type 2 Diabetes Mellitus was evaluated on Serum betatrophin levels (ng/l) (p=0.0001). Serum betatrophin levels were significantly elevated in patients with Type 1 diabetes (322.73 ng/l) compared to those with Type 2 diabetes (144.84 ng/l) and healthy controls (106.19 ng/l).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: